Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

BACKGROUND: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC) concentrations of tenofovir disoproxil fumarate (TDF), by...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Virus Erad
Autors principals: Hill, Andrew, Hughes, Sophie L, Gotham, Dzintars, Pozniak, Anton L
Format: Artigo
Idioma:Inglês
Publicat: Mediscript Ltd 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892670/
https://ncbi.nlm.nih.gov/pubmed/29682298
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars